NCT04755244View on ClinicalTrials.gov

A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05)

PHASE1TerminatedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

May 5, 2021

Primary Completion Date

May 5, 2023

Study Completion Date

August 16, 2023

Conditions
Acute Myeloid LeukemiaAML, Adult
Interventions
DRUG

evorpacept

Fusion protein that blocks CD47-SIRPalpha pathway

DRUG

venetoclax

BCL-2 inhibitor

DRUG

azacitidine

Hypomethylating agent (HMA)

Trial Locations (5)

14263

Roswell Park Comprehensive Cancer Center, Buffalo

27710

Duke University Medical Center, Durham

37203

Vanderbilt University Medical Center, Nashville

60611

Northwestern University Feinberg School of Medicine, Chicago

77030

University of Texas MD Anderson Cancer Center, Houston

Sponsors

Lead Sponsor

ALX Oncology Inc.
All Listed Sponsors
lead

ALX Oncology Inc.

INDUSTRY

NCT04755244 - A Study of Evorpacept (ALX148) With Venetoclax and Azacitidine for Acute Myeloid Leukemia (ASPEN-05) | Biotech Hunter | Biotech Hunter